Xeris Biopharma Holdings, Inc. (XERS) Stock Grade

About Xeris Biopharma Holdings, Inc.'s fundamentals

Xeris Biopharma is a small-cap biotech company with a market capitalization of $1.3 billion that is experiencing strong revenue growth of 43.7% year-over-year, indicating expanding sales momentum. However, the company operates with extremely thin profitability, generating only a 0.2% net margin despite its revenue growth, meaning most sales are consumed by operating costs. The exceptionally high P/E ratio of 2273.2 reflects minimal current earnings relative to market valuation, while the 4.0% return on equity suggests limited efficiency in generating profits from shareholder capital. The company does not pay a dividend, which is typical for growth-stage biotech firms that reinvest earnings into research and development.